Alkem Laboratories delivered mixed Q4 FY26 results with net profit declining 23.8% to ₹236 crore despite achieving strong revenue growth. According to latest reports, the company's revenue from operations jumped 14.6% to ₹3,600 crore compared to the same quarter in the previous year. The profit-to-revenue ratio has deteriorated, signaling rising input costs or higher R&D and regulatory compliance expenditures, with significant margin compression evident as bottom-line growth failed to track revenue gains.
The quarter's performance was significantly impacted by regulatory challenges at the company's manufacturing facilities. On May 2, 2026, Alkem notified exchanges that its Amaliya (Daman) manufacturing facility received 7 observations from the USFDA following an 11-day inspection. The company has committed to addressing these issues within stipulated timelines to prevent further regulatory escalation. Earlier in March 2026, Alkem achieved a regulatory milestone by securing EU GMP certificates for its Daman and Baddi facilities, providing some relief to the regulatory overhang.
The company faces significant leadership uncertainty with CEO Dr. Vikas Gupta announcing his resignation effective June 30, 2026. This transition introduces short-term leadership uncertainty that could impact execution on the company's long-term chronic-therapy growth strategy. The widening gap between Alkem's revenue growth and profit realization suggests the company is trading margins for market share, with increasing cost of regulatory compliance and potential pricing erosion in the US generics market likely squeezing EBITDA margins.
According to latest reports, India sales reached ₹2,324.5 crore in Q4 FY26 with 8.8% YoY growth, while international sales stood at ₹1,222.3 crore, up 25.4% YoY. R&D expenses increased significantly to ₹229.3 crore, representing a 44.67% increase from ₹158.5 crore in Q4 FY25, accounting for 6.4% of total revenue. The company's heavy reliance on anti-infective and acute segments, which are susceptible to seasonal variations, creates a complex operating environment amid intensified US generics pricing pressure.
The mixed earnings profile is likely to cause volatility in the stock as the market digests the profit miss against revenue estimates. After releasing the results, Alkem Laboratories was down by 7.97% in one day. Based on the one-year price targets offered by 19 analysts, the average target price for Alkem Laboratories is ₹5,870.84 with a high estimate of ₹6,913.00 and a low estimate of ₹4,360.00, implying an upside of 9.12% from the current price of ₹5,380.00. The consensus recommendation from 17 brokerage firms indicates an average rating of 2.4, suggesting an 'Outperform' status with a GF Value estimate of ₹6,681.99 for the next year.
